International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 7.16.2020
Good News: FDA Panel Votes to Approve Belantamab Mafodotin
Tuesday’s unanimous ODAC approval of a new treatment called belantamab mafodotin was “good news indeed,” says IMF Chairman Brian G.M. Durie. This first-in-class anti-BCMA therapy is for patients who have received at least four previous therapies and, he says, marks “the first step in the anti-BCMA immune therapy portfolio.”
Register for the Next IMF Patient & Family Webinar
The next IMF Patient & Family Webinar is scheduled for Saturday, August 15, at 1:00 p.m. PT / 4:00 p.m. ET. This two-hour webinar features a panel discussion about the latest treatments for and management of myeloma led by IMF Chairman Dr. Brian G.M. Durie. Panelists include Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen), Dr. Thomas Martin of the University of California San Francisco (UCSF) Health, and patient advocate Jack Aiello.
Calling All Researchers: Submit Your Grant Applications
The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2021 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to receive the applications is Saturday, August 1, 2020. 
Learn More About the Phase III ENDURANCE Trial
In this video, Dr. Shaji Kumar (Mayo Clinic — Rochester, Minnesota) provides the results of the phase III ENDURANCE trial (E1A11). This trial studies the combination of bortezomib, lenalidomide, and dexamethasone (VRd) to see how well they work compared to the combination of carfilzomib, lenalidomide, and dexamethasone (KRd) when treating patients with newly diagnosed multiple myeloma.
And This Too Shall Pass….
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself sipping a tropical beverage next to a private pool, just minutes from the Hawaiian coastline. 
Correction: COVID-19 Emergency Food Assistance Grant Amount Changed
Team Rubicon and the Patient Advocate Foundation have partnered to provide emergency food assistance to those who have cancer, multiple sclerosis, or rheumatoid arthritis, and have been affected by COVID-19. As of July 1, 2020, the one-time financial assistance grant for those in need of financial assistance to purchase food has been changed to $300 per recipient, in order to increase its total reach. The COVID-19 Emergency Food Assistance Program is supported by the Bristol Myers Squibb Foundation.
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

How high of a risk do asymptomatic carriers pose to myeloma patients?
Watch Now
Clinical Trials

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Miracles for Myeloma
Virtual 5K Run/Walk/Bike

Watch a Replay
Post-ASCO / Post-EHA Webinar

Hatfield Hike
Appalachian Trail

Click here to see all events

We Thank Our Sponsors:

Amgen, Bristol-Myers Squibb, Genentech, GSK, Oncopeptides, Inc., Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page